Last reviewed · How we verify
NCT04611607: CAN-SHOCK
Cangrelor in Patients With Acute Myocardial Infarction Undergoing PCI After CPR, Ventilated or Cardiogenic Shock
trial in Acute Myocardial Infarction in 303 participants. Completed in 7 June 2022.
7 June 2022
Quick facts
| Lead sponsor | IHF GmbH - Institut für Herzinfarktforschung |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 303 |
| Start date | 4 May 2021 |
| Primary completion | 7 June 2022 |
| Estimated completion | 7 June 2022 |
| Sites | 10 locations across Austria, Germany |
Conditions studied
- Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →
Sponsor
IHF GmbH - Institut für Herzinfarktforschung — full company profile →
Who can join
18 and older, any sex, with Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This registry will provide information about the efficacy and safety of cangrelor in a very high-risk group of patients with acute myocardial infarction undergoing PCI. It will not only include patients with cardiogenic shock, but a variety of patients not able to swallow tablets, such as those after CPR and/or with invasive or non-invasive ventilation. Therefore it will provide information about the use of cangrelor beyond the current knowledge.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04611607
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myocardial Infarction
Currently open trials in the same condition.
- NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
- NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
- NCT06947135 — Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury · NA · recruiting
- NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
- NCT07522164 — Acute Myocardial Infarction Clinical Cohort · active not recruiting
Other IHF GmbH - Institut für Herzinfarktforschung trials
Trials by the same sponsor.
- NCT05717192 — BENTO - Bronchoscopic Lung Volume Reduction in Severe Emphysema Using Thermoablation · NA · recruiting
- NCT04612179 — Post-Market Registry to Evaluate the Safety and Efficacy of the The SUPRAFLEX CRUZ™ Sirolimus Eluting Coronary Stent Sys · completed
- NCT04398654 — Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes · NA · active not recruiting
- NCT04335188 — COVID-19 Registry Rhineland-Palatinate (Germany) · completed
- NCT03863132 — accuRate Evaluation of Benefit With Optimal Medical Treatment With or Without Transcatheter Valve Repair of PARADOXical · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04611607 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IHF GmbH - Institut für Herzinfarktforschung
- Last refreshed: 27 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04611607.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing